Form 4: Astera Labs President and COO Sells Over 165,000 Shares Under Pre-Arranged Trading Plan

Astera Labs' President and COO, Sanjay Gajendra, sold 165,000 shares of common stock for approximately $16.2 million through a pre-established Rule 10b5-1 trading plan.

Summary

• Sanjay Gajendra, President and COO, Director, and 10% Owner of Astera Labs, Inc. (ALAB), sold a total of 165,000 shares of common stock.
• The sales occurred on May 27, 2025, under a Rule 10b5-1 trading plan adopted on November 30, 2024.
• The shares were sold at weighted average prices ranging from $98.1727 to $98.2718 per share.
• Specifically, 125,000 shares were sold at $98.2718, 20,000 shares at $98.175, and another 20,000 shares at $98.1727.
• Following these transactions, Mr. Gajendra directly owns 2,262,318 shares and indirectly owns 7,525,545 shares through various estate planning trusts (Trust 1, Trust 2, and Trust 3).

Sentiment

Score: 5

Explanation: While insider selling can be viewed negatively, the fact that it was executed under a pre-planned Rule 10b5-1 plan mitigates concerns about opportunistic selling, making the overall sentiment neutral. However, the sheer volume and value of the sale might still cause some investor apprehension.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and automated transaction rather than a reaction to new, negative information, which provides transparency and reduces concerns about opportunistic selling.

Negatives

• Insider selling, even under a 10b5-1 plan, can be perceived negatively by investors as it reduces the insider's direct stake in the company.
• The sale represents a significant monetary value, approximately $16.2 million, which could be interpreted as a lack of confidence by some investors, despite the 10b5-1 plan.

Risks

• Investor perception risk: While the sale was pre-planned, significant insider selling can sometimes lead to negative market sentiment or speculation about the company's future prospects.

Future Outlook

NA

Management Comments

• "The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2024."
• "The Reporting Person disclaims beneficial ownership of these securities [held by trusts], except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."

Industry Context

This is an insider transaction report specific to Astera Labs. It doesn't directly relate to broader industry trends, but insider selling is a common occurrence across all industries as executives manage their personal equity holdings.

Stakeholder Impact

• Shareholders: May interpret the insider sale differently; some may view it as a routine diversification, while others might see it as a negative signal, potentially influencing short-term stock price movements.

Next Steps

• Continued execution of the Rule 10b5-1 trading plan, if further sales are scheduled.

Key Dates

Recommendation

Keywords

Astera Labs, ALAB, Form 4, insider trading, insider sale, Rule 10b5-1, Sanjay Gajendra, common stock, beneficial ownership, SEC filing